secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zeo ScientifiX, Inc. (ZEOX)
CIK:        0001557376
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0001829126-24-006533
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Zeo ScientifiX partners with Physicians Group for Phase 2 clinical trials
-------------------------------------------------------------------------

- Physicians Group operates 75 clinics and 750+ clinicians, treating 1,500-2,000 patients monthly.
- Collaboration targets Phase 2 trials of Zofin™ for several indications and other pipeline products.
- Zeo completed Phase 1 for Zofin; aims for FDA approval for various diseases and chronic conditions.
- Regenerative medicine market projected to reach ~$175B by 2032 with 22.8% CAGR per Precedence Research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557376/000182912624006533/0001829126-24-006533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557376/000182912624006533/zeoscientifix_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-24-006533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer